These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 24427287)

  • 1. Phage display of the serpin alpha-1 proteinase inhibitor randomized at consecutive residues in the reactive centre loop and biopanned with or without thrombin.
    Scott BM; Matochko WL; Gierczak RF; Bhakta V; Derda R; Sheffield WP
    PLoS One; 2014; 9(1):e84491. PubMed ID: 24427287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression screening of bacterial libraries of recombinant alpha-1 proteinase inhibitor variants for candidates with thrombin inhibitory capacity.
    Bhakta V; Gierczak RF; Sheffield WP
    J Biotechnol; 2013 Dec; 168(4):373-81. PubMed ID: 24140600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fusion of the C-terminal triskaidecapeptide of hirudin variant 3 to alpha1-proteinase inhibitor M358R increases the serpin-mediated rate of thrombin inhibition.
    Roddick LA; Bhakta V; Sheffield WP
    BMC Biochem; 2013 Nov; 14():31. PubMed ID: 24215622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of mammalian and bacterial expression library screening to detect recombinant alpha-1 proteinase inhibitor variants with enhanced thrombin inhibitory capacity.
    Gierczak RF; Bhakta V; Xie M; Sheffield WP
    J Biotechnol; 2015 Aug; 208():54-62. PubMed ID: 26043905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of an alpha-1 antitrypsin variant with enhanced specificity for factor XIa by phage display, bacterial expression, and combinatorial mutagenesis.
    Bhakta V; Hamada M; Nouanesengsy A; Lapierre J; Perruzza DL; Sheffield WP
    Sci Rep; 2021 Mar; 11(1):5565. PubMed ID: 33692375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The appended tail region of heparin cofactor II and additional reactive centre loop mutations combine to increase the reactivity and specificity of alpha1-proteinase inhibitor M358R for thrombin.
    Sutherland JS; Bhakta V; Sheffield WP
    Thromb Haemost; 2007 Nov; 98(5):1014-23. PubMed ID: 18000606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Full or partial substitution of the reactive center loop of alpha-1-proteinase inhibitor by that of heparin cofactor II: P1 Arg is required for maximal thrombin inhibition.
    Filion ML; Bhakta V; Nguyen LH; Liaw PS; Sheffield WP
    Biochemistry; 2004 Nov; 43(46):14864-72. PubMed ID: 15544357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-1 proteinase inhibitor M358R reduces thrombin generation when displayed on the surface of cells expressing tissue factor.
    Gierczak RF; Pepler L; Bhagirath V; Liaw PC; Sheffield WP
    Thromb Res; 2014 Nov; 134(5):1142-9. PubMed ID: 25242242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The transferable tail: fusion of the N-terminal acidic extension of heparin cofactor II to alpha1-proteinase inhibitor M358R specifically increases the rate of thrombin inhibition.
    Sutherland JS; Bhakta V; Filion ML; Sheffield WP
    Biochemistry; 2006 Sep; 45(38):11444-52. PubMed ID: 16981704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The M358R variant of α(1)-proteinase inhibitor inhibits coagulation factor VIIa.
    Sheffield WP; Bhakta V
    Biochem Biophys Res Commun; 2016 Feb; 470(3):710-713. PubMed ID: 26797521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective screening of a large phage display library of plasminogen activator inhibitor 1 mutants to localize interaction sites with either thrombin or the variable region 1 of tissue-type plasminogen activator.
    van Meijer M; Roelofs Y; Neels J; Horrevoets AJ; van Zonneveld AJ; Pannekoek H
    J Biol Chem; 1996 Mar; 271(13):7423-8. PubMed ID: 8631768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a novel recombinant serpin with potential antithrombotic properties.
    Hopkins PC; Crowther DC; Carrell RW; Stone SR
    J Biol Chem; 1995 May; 270(20):11866-71. PubMed ID: 7744836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stepwise Reversion of Multiply Mutated Recombinant Antitrypsin Reveals a Selective Inhibitor of Coagulation Factor XIa as Active as the M358R Variant.
    Hamada M; Bhakta V; Andres SN; Sheffield WP
    Front Cardiovasc Med; 2021; 8():647405. PubMed ID: 33816577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties.
    Ehrlich HJ; Gebbink RK; Keijer J; Linders M; Preissner KT; Pannekoek H
    J Biol Chem; 1990 Aug; 265(22):13029-35. PubMed ID: 1695900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein engineering of chimeric Serpins: an investigation into effects of the serpin scaffold and reactive centre loop length.
    Bottomley SP; Stone SR
    Protein Eng; 1998 Dec; 11(12):1243-7. PubMed ID: 9930674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serpin Phage Display: The Use of a T7 System to Probe Reactive Center Loop Libraries with Different Serine Proteinases.
    de Souza LR; Scott BM; Bhakta V; Donkor DA; Perruzza DL; Sheffield WP
    Methods Mol Biol; 2018; 1826():41-64. PubMed ID: 30194592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of thrombus size in murine models of thrombosis following administration of recombinant α1-proteinase inhibitor mutant proteins.
    Sheffield WP; Eltringham-Smith LJ; Bhakta V; Gataiance S
    Thromb Haemost; 2012 May; 107(5):972-84. PubMed ID: 22370677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retention of thrombin inhibitory activity by recombinant serpins expressed as integral membrane proteins tethered to the surface of mammalian cells.
    Gierczak RF; Sutherland JS; Bhakta V; Toltl LJ; Liaw PC; Sheffield WP
    J Thromb Haemost; 2011 Dec; 9(12):2424-35. PubMed ID: 21972922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The selection performance of an antibody library displayed on filamentous phage coat proteins p9, p3 and truncated p3.
    Huovinen T; Syrjänpää M; Sanmark H; Seppä T; Akter S; Khan LM; Lamminmäki U
    BMC Res Notes; 2014 Sep; 7():661. PubMed ID: 25238965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.
    Stoop AA; Eldering E; Dafforn TR; Read RJ; Pannekoek H
    J Mol Biol; 2001 Jan; 305(4):773-83. PubMed ID: 11162091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.